Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol

American Journal of Cardiology

Volumn 91, Issue 9, 2003, Pages 1134-1136

  Case, Christopher C ^b   Jacobson, Terry A ^b   Roberts, Susan ^b   Buckley, Ann ^b   Murtaugh, Kathleen M ^b   Sung, Jennifer C Y ^b   Gause, Douglas ^b   Varas, Cristina ^b   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ADULT; ARTICLE; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; EDUCATION PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0344511815     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00167-X     Document Type: Article

References (10)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomized placebo-controlled trial . Lancet. 360:2002;7-22.
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
3. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94. Hyattsville, MD: U.S. Department of Health and Human Services; 1994.
4. Jacobson T.A., Griffiths G.G., Varas C., Gause D., Sung J.C.Y., Ballantyne C.M. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering drug therapy based on updated NHANES III data. Arch Intern Med. 160:2000;1361-1369.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
6. Mohadjer L, Montaquila J, Waksberg J, Bell B, James P, Flores-Cervantes I, Montes M. National Health and Nutrition Examination Survey III: weighting and estimation methodology: executive summary. Hyattsville, MD: National Center for Health Statistics; February 1996.
7. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention . Atherosclerosis. 140:1998;199-270.
8. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention a randomized controlled trial . JAMA. 287:2002;3215-3222.
9. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., Keech A., Packard C., Simes J., Byington R., Furberg C.D. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors the Prospective Pravastatin Pooling Project . Circulation. 102:2000;1893-1900.
10. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.